

# Norbert Weissmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8461932/publications.pdf>

Version: 2024-02-01

200  
papers

14,536  
citations

20817

60  
h-index

21540

114  
g-index

205  
all docs

205  
docs citations

205  
times ranked

14357  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reversal of experimental pulmonary hypertension by PDGF inhibition. <i>Journal of Clinical Investigation</i> , 2005, 115, 2811-2821.	8.2	917
2	Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. <i>Lancet</i> , The, 2002, 360, 895-900.	13.7	720
3	Cellular and Molecular Basis of Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S20-S31.	2.8	714
4	Nox family NADPH oxidases: Molecular mechanisms of activation. <i>Free Radical Biology and Medicine</i> , 2014, 76, 208-226.	2.9	546
5	Nox4 Is a Protective Reactive Oxygen Species Generating Vascular NADPH Oxidase. <i>Circulation Research</i> , 2012, 110, 1217-1225.	4.5	540
6	Pulmonary hypertension in chronic lung disease and hypoxia. <i>European Respiratory Journal</i> , 2019, 53, 1801914.	6.7	428
7	Post-Stroke Inhibition of Induced NADPH Oxidase Type 4 Prevents Oxidative Stress and Neurodegeneration. <i>PLoS Biology</i> , 2010, 8, e1000479.	5.6	377
8	Hypoxia-Dependent Regulation of Nonphagocytic NADPH Oxidase Subunit NOX4 in the Pulmonary Vasculature. <i>Circulation Research</i> , 2007, 101, 258-267.	4.5	317
9	Immune and Inflammatory Cell Involvement in the Pathology of Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 897-908.	5.6	296
10	Inducible NOS Inhibition Reverses Tobacco-Smoke-Induced Emphysema and Pulmonary Hypertension in Mice. <i>Cell</i> , 2011, 147, 293-305.	28.9	293
11	Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 19093-19098.	7.1	273
12	NADPH oxidases in cardiovascular disease. <i>Free Radical Biology and Medicine</i> , 2010, 49, 687-706.	2.9	241
13	Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. <i>Nature Medicine</i> , 2014, 20, 1289-1300.	30.7	233
14	Chronic Sildenafil Treatment Inhibits Monocrotaline-induced Pulmonary Hypertension in Rats. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 39-45.	5.6	230
15	The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 957-967.	0.6	221
16	Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling. <i>Circulation</i> , 2006, 113, 286-295.	1.6	208
17	Inhibition of MicroRNA-17 Improves Lung and Heart Function in Experimental Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 409-419.	5.6	206
18	Long Noncoding RNA MANTIS Facilitates Endothelial Angiogenic Function. <i>Circulation</i> , 2017, 136, 65-79.	1.6	196

#	ARTICLE	IF	CITATIONS
19	Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. <i>Free Radical Biology and Medicine</i> , 2004, 36, 1279-1288.	2.9	183
20	Activation of TRPC6 channels is essential for lung ischaemiaâ€“reperfusion induced oedema in mice. <i>Nature Communications</i> , 2012, 3, 649.	12.8	162
21	Essential role of complex II of the respiratory chain in hypoxia-induced ROS generation in the pulmonary vasculature. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2003, 284, L710-L719.	2.9	148
22	Oxygen-dependent expression of cytochrome c oxidase subunit 4-2 gene expression is mediated by transcription factors RBPJ, CXXC5 and CHCHD2. <i>Nucleic Acids Research</i> , 2013, 41, 2255-2266.	14.5	146
23	Phosphodiesterase 1 Upregulation in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2007, 115, 2331-2339.	1.6	139
24	Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling. <i>Circulation</i> , 2008, 118, 2081-2090.	1.6	139
25	Oxygen sensing and signal transduction in hypoxic pulmonary vasoconstriction. <i>European Respiratory Journal</i> , 2016, 47, 288-303.	6.7	120
26	NOX4 Regulates ROS Levels Under Normoxic and Hypoxic Conditions, Triggers Proliferation, and Inhibits Apoptosis in Pulmonary Artery Adventitial Fibroblasts. <i>Antioxidants and Redox Signaling</i> , 2008, 10, 1687-1698.	5.4	118
27	Pathophysiology and Treatment of High-Altitude Pulmonary Vascular Disease. <i>Circulation</i> , 2015, 131, 582-590.	1.6	108
28	Hypoxia-inducible factor signaling in pulmonary hypertension. <i>Journal of Clinical Investigation</i> , 2020, 130, 5638-5651.	8.2	104
29	Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response. <i>FASEB Journal</i> , 2008, 22, 4306-4315.	0.5	100
30	Expression profiling of laser-microdissected intrapulmonary arteries in hypoxia-induced pulmonary hypertension. <i>Respiratory Research</i> , 2005, 6, 109.	3.6	99
31	Antiremodeling Effects of Iloprost and the Dual-Selective Phosphodiesterase 3/4 Inhibitor Tolafentrine in Chronic Experimental Pulmonary Hypertension. <i>Circulation Research</i> , 2004, 94, 1101-1108.	4.5	97
32	Lysyl Oxidases Play a Causal Role in Vascular Remodeling in Clinical and Experimental Pulmonary Arterial Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1446-1458.	2.4	97
33	Impact of Mitochondria and NADPH Oxidases on Acute and Sustained Hypoxic Pulmonary Vasoconstriction. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2006, 34, 505-513.	2.9	90
34	Mitochondrial Complex IV Subunit 4 Isoform 2 Is Essential for Acute Pulmonary Oxygen Sensing. <i>Circulation Research</i> , 2017, 121, 424-438.	4.5	90
35	Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2016, 48, 1137-1149.	6.7	89
36	Identification of novel Nox4 splice variants with impact on ROS levels in A549 cells. <i>Biochemical and Biophysical Research Communications</i> , 2005, 329, 32-39.	2.1	88

#	ARTICLE	IF	CITATIONS
37	Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H <sub>2</sub> O <sub>2</sub> ?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 279, L683-L690.	2.9	87
38	In vivo TRPC functions in the cardiopulmonary vasculature. Cell Calcium, 2007, 42, 233-244.	2.4	84
39	Physiologic basis for the treatment of pulmonary hypertension. Translational Research, 2001, 138, 287-297.	2.3	81
40	Cellular and molecular mechanisms of hypoxia-inducible factor driven vascular remodeling. Thrombosis and Haemostasis, 2007, 97, 774-787.	3.4	81
41	Riociguat for the treatment of pulmonary hypertension. Expert Opinion on Investigational Drugs, 2011, 20, 567-576.	4.1	81
42	Redox-mediated signal transduction by cardiovascular Nox NADPH oxidases. Journal of Molecular and Cellular Cardiology, 2014, 73, 70-79.	1.9	81
43	Stimulation of Soluble Guanylate Cyclase Prevents Cigarette Smoke-induced Pulmonary Hypertension and Emphysema. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1359-1373.	5.6	80
44	Fhl-1, a New Key Protein in Pulmonary Hypertension. Circulation, 2008, 118, 1183-1194.	1.6	79
45	ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 373-385.	5.6	78
46	Classical Transient Receptor Potential Channel 1 in Hypoxia-induced Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1451-1459.	5.6	77
47	A RASSF1A-HIF1 $\alpha$ loop drives Warburg effect in cancer and pulmonary hypertension. Nature Communications, 2019, 10, 2130.	12.8	77
48	cDNA Array Hybridization after Laser-Assisted Microdissection from Nonneoplastic Tissue. American Journal of Pathology, 2002, 160, 81-90.	3.8	75
49	Novel and Emerging Therapies for Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 394-400.	5.6	75
50	Low-dose Systemic Phosphodiesterase Inhibitors Amplify the Pulmonary Vasodilatory Response to Inhaled Prostacyclin in Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 1500-1506.	5.6	73
51	p38 MAPK Inhibition Improves Heart Function in Pressure-Loaded Right Ventricular Hypertrophy. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 603-614.	2.9	72
52	Hypoxic vasoconstriction in buffer-perfused rabbit lungs. Respiration Physiology, 1995, 100, 159-169.	2.7	71
53	Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. Nature Communications, 2019, 10, 2204.	12.8	69
54	Hypoxia induces Kv channel current inhibition by increased NADPH oxidase-derived reactive oxygen species. Free Radical Biology and Medicine, 2012, 52, 1033-1042.	2.9	68

#	ARTICLE	IF	CITATIONS
55	Nox Family NADPH Oxidases in Mechano-Transduction: Mechanisms and Consequences. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 887-898.	5.4	68
56	Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition. <i>Cardiovascular Research</i> , 2010, 85, 232-240.	3.8	66
57	Mitochondrial Hyperpolarization in Pulmonary Vascular Remodeling. Mitochondrial Uncoupling Protein Deficiency as Disease Model. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2013, 49, 358-367.	2.9	66
58	Amplified canonical transforming growth factor- $\beta$ signalling <i>via</i> heat shock protein 90 in pulmonary fibrosis. <i>European Respiratory Journal</i> , 2017, 49, 1501941.	6.7	66
59	Impact of the mitochondria-targeted antioxidant MitoQ on hypoxia-induced pulmonary hypertension. <i>European Respiratory Journal</i> , 2018, 51, 1701024.	6.7	64
60	Inhaled Iloprost Reverses Vascular Remodeling in Chronic Experimental Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 172, 358-363.	5.6	62
61	Cytochrome <i>c</i> oxidase subunit 4 isoform 2 knockout mice show reduced enzyme activity, airway hyporeactivity, and lung pathology. <i>FASEB Journal</i> , 2012, 26, 3916-3930.	0.5	62
62	Function of NADPH Oxidase 1 in Pulmonary Arterial Smooth Muscle Cells After Monocrotaline-Induced Pulmonary Vascular Remodeling. <i>Antioxidants and Redox Signaling</i> , 2013, 19, 2213-2231.	5.4	62
63	Oxygen sensors in hypoxic pulmonary vasoconstriction. <i>Cardiovascular Research</i> , 2006, 71, 620-629.	3.8	61
64	PAR-2 Inhibition Reverses Experimental Pulmonary Hypertension. <i>Circulation Research</i> , 2012, 110, 1179-1191.	4.5	61
65	Effects of hypercapnia with and without acidosis on hypoxic pulmonary vasoconstriction. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009, 297, L977-L983.	2.9	60
66	Acute O <sub>2</sub> sensing through HIF $2\alpha$ -dependent expression of atypical cytochrome oxidase subunits in arterial chemoreceptors. <i>Science Signaling</i> , 2020, 13, .	3.6	60
67	NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001, 280, L638-L645.	2.9	59
68	Intermedin/adrenomedullin-2 is a hypoxia-induced endothelial peptide that stabilizes pulmonary microvascular permeability. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009, 297, L837-L845.	2.9	59
69	Dysregulation of the IL-13 Receptor System. A Novel Pathomechanism in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 805-818.	5.6	59
70	Basic features of hypoxic pulmonary vasoconstriction in mice. <i>Respiratory Physiology and Neurobiology</i> , 2004, 139, 191-202.	1.6	58
71	Endothelin-1 Inhibits Background Two-Pore Domain Channel TASK-1 in Primary Human Pulmonary Artery Smooth Muscle Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2009, 41, 476-483.	2.9	58
72	Organizers and activators: Cytosolic Nox proteins impacting on vascular function. <i>Free Radical Biology and Medicine</i> , 2017, 109, 22-32.	2.9	58

#	ARTICLE	IF	CITATIONS
73	Molecular mechanisms of hypoxia-induced pulmonary arterial smooth muscle cell alterations in pulmonary hypertension. <i>Journal of Physiology</i> , 2016, 594, 1167-1177.	2.9	57
74	Identification of right heart-enriched genes in a murine model of chronic outflow tract obstruction. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 49, 598-605.	1.9	56
75	Coaerosolization of Phosphodiesterase Inhibitors Markedly Enhances the Pulmonary Vasodilatory Response to Inhaled Iloprost in Experimental Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 1694-1700.	5.6	54
76	Impact of HIF-1 $\alpha$ and HIF-2 $\alpha$ on proliferation and migration of human pulmonary artery fibroblasts in hypoxia. <i>FASEB Journal</i> , 2006, 20, 163-165.	0.5	52
77	Unchanged NADPH Oxidase Activity in Nox1-Nox2-Nox4 Triple Knockout Mice: What Do NADPH-Stimulated Chemiluminescence Assays Really Detect?. <i>Antioxidants and Redox Signaling</i> , 2016, 24, 392-399.	5.4	52
78	Effects of Mitochondrial Inhibitors and Uncouplers on Hypoxic Vasoconstriction in Rabbit Lungs. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2003, 29, 721-732.	2.9	51
79	Diacylglycerol regulates acute hypoxic pulmonary vasoconstriction via TRPC6. <i>Respiratory Research</i> , 2011, 12, 20.	3.6	51
80	Pulmonary hypertension in chronic obstructive pulmonary disease. <i>British Journal of Pharmacology</i> , 2021, 178, 132-151.	5.4	51
81	Hypoxia-Dependent Reactive Oxygen Species Signaling in the Pulmonary Circulation: Focus on Ion Channels. <i>Antioxidants and Redox Signaling</i> , 2015, 22, 537-552.	5.4	50
82	Hypoxia- and non-hypoxia-related pulmonary hypertension – Established and new therapies. <i>Cardiovascular Research</i> , 2006, 72, 30-40.	3.8	49
83	Inactivation of sestrin 2 induces TGF- $\beta$ 2 signaling and partially rescues pulmonary emphysema in a mouse model of COPD. <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 246-253.	2.4	49
84	Shear force sensing of epithelial Na <sup>+</sup> channel (ENaC) relies on N-glycosylated asparagines in the palm and knuckle domains of ENaC. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 717-726.	7.1	49
85	Arterial hypertension in a murine model of sleep apnea. <i>Journal of Hypertension</i> , 2014, 32, 300-305.	0.5	47
86	Hypoxic Pulmonary Hypertension in Mice with Constitutively Active Platelet-Derived Growth Factor Receptor-2. <i>Pulmonary Circulation</i> , 2011, 1, 259-268.	1.7	44
87	Evidence for a role of protein kinase C in hypoxic pulmonary vasoconstriction. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1999, 276, L90-L95.	2.9	43
88	BDNF/TrkB Signaling Augments Smooth Muscle Cell Proliferation in Pulmonary Hypertension. <i>American Journal of Pathology</i> , 2012, 181, 2018-2029.	3.8	43
89	Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1692.	2.6	43
90	Inflammatory Mediators Drive Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential Biomarkers. <i>Frontiers in Physiology</i> , 2018, 9, 609.	2.8	42

#	ARTICLE	IF	CITATIONS
91	Endothelin-1 driven proliferation of pulmonary arterial smooth muscle cells is c-fos dependent. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 54, 137-148.	2.8	41
92	Hypoxic pulmonary vasoconstriction: a multifactorial response?. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001, 281, L314-L317.	2.9	40
93	The Role of Transient Receptor Potential Channel 6 Channels in the Pulmonary Vasculature. <i>Frontiers in Immunology</i> , 2017, 8, 707.	4.8	39
94	Evidence for the Fucoidan/P-Selectin Axis as a Therapeutic Target in Hypoxia-induced Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1407-1420.	5.6	39
95	Bypassing mitochondrial complex III using alternative oxidase inhibits acute pulmonary oxygen sensing. <i>Science Advances</i> , 2020, 6, eaba0694.	10.3	39
96	Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. <i>BMC Pulmonary Medicine</i> , 2010, 10, 26.	2.0	38
97	Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001, 281, L1361-L1368.	2.9	37
98	Heme Oxygenase-2 and Large-Conductance Ca <sup>2+</sup> -activated K <sup>+</sup> Channels. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 353-364.	5.6	37
99	Alternative Oxidase Attenuates Cigarette Smoke-induced Lung Dysfunction and Tissue Damage. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019, 60, 515-522.	2.9	37
100	Targeting Jak-Stat Signaling in Experimental Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, 64, 100-114.	2.9	37
101	Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury. <i>BMC Pulmonary Medicine</i> , 2008, 8, 25.	2.0	36
102	Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-GMP signaling. <i>FASEB Journal</i> , 2008, 22, 30-40.	0.5	36
103	Histological Characterization of Mast Cell Chymase in Patients with Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease. <i>Pulmonary Circulation</i> , 2014, 4, 128-136.	1.7	36
104	Pressure overload leads to an increased accumulation and activity of mast cells in the right ventricle. <i>Physiological Reports</i> , 2017, 5, e13146.	1.7	36
105	The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009, 297, L658-L665.	2.9	35
106	Redox signaling and reactive oxygen species in hypoxic pulmonary vasoconstriction. <i>Respiratory Physiology and Neurobiology</i> , 2010, 174, 282-291.	1.6	35
107	Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling. <i>International Journal of Cardiology</i> , 2013, 167, 2630-2637.	1.7	35
108	Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19. <i>Blood Advances</i> , 2022, 6, 1074-1087.	5.2	35

#	ARTICLE	IF	CITATIONS
109	Downregulation of hypoxic vasoconstriction by chronic hypoxia in rabbits: effects of nitric oxide. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003, 284, H931-H938.	3.2	34
110	Pressure Overload Creates Right Ventricular Diastolic Dysfunction in a Mouse Model: Assessment by Echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2015, 28, 828-843.	2.8	33
111	CRISPR/Cas9-mediated knockout of p22phox leads to loss of Nox1 and Nox4, but not Nox5 activity. <i>Redox Biology</i> , 2016, 9, 287-295.	9.0	33
112	Nestin-expressing vascular wall cells drive development of pulmonary hypertension. <i>European Respiratory Journal</i> , 2016, 47, 876-888.	6.7	33
113	Detection of reactive oxygen species in isolated, perfused lungs by electron spin resonance spectroscopy. <i>Respiratory Research</i> , 2005, 6, 86.	3.6	32
114	Increased S100A4 expression in the vasculature of human COPD lungs and murine model of smoke-induced emphysema. <i>Respiratory Research</i> , 2015, 16, 127.	3.6	32
115	Congenital erythropoietin over-expression causes "anti-pulmonary hypertensive" structural and functional changes in mice, both in normoxia and hypoxia. <i>Thrombosis and Haemostasis</i> , 2005, 94, 630-638.	3.4	31
116	Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. <i>Respiratory Research</i> , 2005, 6, 76.	3.6	31
117	Structural and functional prevention of hypoxia-induced pulmonary hypertension by individualized exercise training in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014, 306, L986-L995.	2.9	31
118	Lung Ischaemia"Reperfusion Injury: The Role of Reactive Oxygen Species. <i>Advances in Experimental Medicine and Biology</i> , 2017, 967, 195-225.	1.6	29
119	Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice. <i>PLoS ONE</i> , 2015, 10, e0129327.	2.5	29
120	Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice. <i>International Journal of Cardiology</i> , 2016, 216, 85-91.	1.7	28
121	TRPV4 channels are essential for alveolar epithelial barrier function as protection from lung edema. <i>JCI Insight</i> , 2020, 5, .	5.0	28
122	Hypoxia-induced pulmonary hypertension: Different impact of iloprost, sildenafil, and nitric oxide. <i>Respiratory Medicine</i> , 2007, 101, 2125-2132.	2.9	27
123	Paxillin Regulates Pulmonary Arterial Smooth Muscle Cell Function in Pulmonary Hypertension. <i>American Journal of Pathology</i> , 2012, 181, 1621-1633.	3.8	27
124	Lung epithelium damage in COPD "An unstoppable pathological event?. <i>Cellular Signalling</i> , 2020, 68, 109540.	3.6	27
125	The Cytosolic NADPH Oxidase Subunit NoxO1 Promotes an Endothelial Stalk Cell Phenotype. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1558-1565.	2.4	26
126	Pathobiology, pathology and genetics of pulmonary hypertension: Update from the Cologne Consensus Conference 2018. <i>International Journal of Cardiology</i> , 2018, 272, 4-10.	1.7	26

#	ARTICLE	IF	CITATIONS
127	Riociguat for treatment of pulmonary hypertension in COPD: a translational study. <i>European Respiratory Journal</i> , 2019, 53, 1802445.	6.7	25
128	Nitro blue tetrazolium inhibits but does not mimic hypoxic vasoconstriction in isolated rabbit lungs. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1998, 274, L721-L727.	2.9	24
129	Nitric Oxide (NO)-Dependent but Not NO-Independent Guanylate Cyclase Activation Attenuates Hypoxic Vasoconstriction in Rabbit Lungs. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2000, 23, 222-227.	2.9	24
130	Oxidative injury of the pulmonary circulation in the perinatal period: Short- and long-term consequences for the human cardiopulmonary system. <i>Pulmonary Circulation</i> , 2017, 7, 55-66.	1.7	24
131	Alveolar epithelial barrier functions in ventilated perfused rabbit lungs. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001, 280, L896-L904.	2.9	23
132	Direct eicosanoid profiling of the hypoxic lung by comprehensive analysis via capillary liquid chromatography with dual online photodiode-array and tandem mass-spectrometric detection. <i>Analytical and Bioanalytical Chemistry</i> , 2008, 390, 697-714.	3.7	23
133	Impact of S-Adenosylmethionine Decarboxylase 1 on Pulmonary Vascular Remodeling. <i>Circulation</i> , 2014, 129, 1510-1523.	1.6	23
134	NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. <i>Nature Metabolism</i> , 2020, 2, 532-546.	11.9	23
135	Chronic Obstructive Pulmonary Disease and the Cardiovascular System: Vascular Repair and Regeneration as a Therapeutic Target. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 649512.	2.4	23
136	Urodilatin, a Natriuretic Peptide Stimulating Particulate Guanylate Cyclase, and the Phosphodiesterase 5 Inhibitor Dipyridamole Attenuate Experimental Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2001, 25, 219-225.	2.9	22
137	Cigarette smoke causes acute airway disease and exacerbates chronic obstructive lung disease in neonatal mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2016, 311, L602-L610.	2.9	22
138	SPARC, a Novel Regulator of Vascular Cell Function in Pulmonary Hypertension. <i>Circulation</i> , 2022, 145, 916-933.	1.6	21
139	Novel soluble guanylyl cyclase stimulator BAY 41-2272 attenuates ischemia-reperfusion-induced lung injury. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009, 296, L462-L469.	2.9	20
140	Mitochondrial complex II is essential for hypoxia-induced pulmonary vasoconstriction of intra- but not of pre-acinar arteries. <i>Cardiovascular Research</i> , 2012, 93, 702-710.	3.8	20
141	Effects of hypercapnia and NO synthase inhibition in sustained hypoxic pulmonary vasoconstriction. <i>Respiratory Research</i> , 2012, 13, 7.	3.6	20
142	Functional and Muscular Adaptations in an Experimental Model for Isometric Strength Training in Mice. <i>PLoS ONE</i> , 2013, 8, e79069.	2.5	20
143	NADPH oxidases—do they play a role in TRPC regulation under hypoxia?. <i>Pflügers Archiv European Journal of Physiology</i> , 2016, 468, 23-41.	2.8	19
144	Hypoxia- or PDGF-BB-dependent paxillin tyrosine phosphorylation in pulmonary hypertension is reversed by HIF-1 $\beta$ depletion or imatinib treatment. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1288-1303.	3.4	18

#	ARTICLE	IF	CITATIONS
145	Effects of Dimethylarginine Dimethylaminohydrolase <sup>1</sup> Overexpression on the Response of the Pulmonary Vasculature to Hypoxia. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2013, 49, 491-500.	2.9	17
146	Sestrin 2 Protein Regulates Platelet-derived Growth Factor Receptor $\beta^2$ (Pdgfr $\beta^2$ ) Expression by Modulating Proteasomal and Nrf2 Transcription Factor Functions. <i>Journal of Biological Chemistry</i> , 2015, 290, 9738-9752.	3.4	17
147	FHL-1 is not involved in pressure overload-induced maladaptive right ventricular remodeling and dysfunction. <i>Basic Research in Cardiology</i> , 2020, 115, 17.	5.9	17
148	Amelioration of elastase $\alpha$ -induced lung emphysema and reversal of pulmonary hypertension by pharmacological iNOS inhibition in mice. <i>British Journal of Pharmacology</i> , 2021, 178, 152-171.	5.4	17
149	Effects of arachidonic acid metabolism on hypoxic vasoconstriction in rabbit lungs. <i>European Journal of Pharmacology</i> , 1998, 356, 231-237.	3.5	16
150	Cofilin, a hypoxia $\alpha$ -regulated protein in murine lungs identified by 2D-DE: Role of the cytoskeletal protein cofilin in pulmonary hypertension. <i>Proteomics</i> , 2013, 13, 75-88.	2.2	16
151	Impairment of hypoxic pulmonary vasoconstriction in acute respiratory distress syndrome. <i>European Respiratory Review</i> , 2021, 30, 210059.	7.1	16
152	Resolvin E1 Improves Mitochondrial Function in Human Alveolar Epithelial Cells during Severe Inflammation. <i>Lipids</i> , 2019, 54, 53-65.	1.7	15
153	Hypoxic pulmonary vasoconstriction in isolated mouse pulmonary arterial vessels. <i>Experimental Physiology</i> , 2018, 103, 1185-1191.	2.0	14
154	Nebulization of the acidified sodium nitrite formulation attenuates acute hypoxic pulmonary vasoconstriction. <i>Respiratory Research</i> , 2010, 11, 81.	3.6	13
155	Deletion of NoxO1 limits atherosclerosis development in female mice. <i>Redox Biology</i> , 2020, 37, 101713.	9.0	13
156	Flow Cytometry-Based Quantification of Neutrophil Extracellular Traps Shows an Association with Hypercoagulation in Septic Shock and Hypocoagulation in Postsurgical Systemic Inflammation $\alpha$ ”A Proof-of-Concept Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 174.	2.4	13
157	Myeloid-cell-specific deletion of inducible nitric oxide synthase protects against smoke-induced pulmonary hypertension in mice. <i>European Respiratory Journal</i> , 2022, 59, 2101153.	6.7	13
158	The PDE inhibitor zaprinast enhances NO-mediated protection against vascular leakage in reperfused lungs. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2000, 279, L496-L502.	2.9	12
159	Recent advances in oxygen sensing and signal transduction in hypoxic pulmonary vasoconstriction. <i>Journal of Applied Physiology</i> , 2017, 123, 1647-1656.	2.5	12
160	Hypoxic Pulmonary Vasoconstriction-Triggered by an Increase in Reactive Oxygen Species?. <i>Novartis Foundation Symposium</i> , 0, , 196-213.	1.1	12
161	Animal models of pulmonary hypertension: role in translational research. <i>Drug Discovery Today: Disease Models</i> , 2010, 7, 89-97.	1.2	11
162	Ltp4 regulates Pdgfr $\beta^2$ expression via TGF $\beta^2$ -dependent modulation of Nrf2 transcription factor function. <i>Matrix Biology</i> , 2017, 59, 109-120.	3.6	11

#	ARTICLE	IF	CITATIONS
163	Lung developmental arrest caused by PDGF-A deletion: consequences for the adult mouse lung. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 318, L831-L843.	2.9	11
164	Adenylate Kinase 4" A Key Regulator of Proliferation and Metabolic Shift in Human Pulmonary Arterial Smooth Muscle Cells via Akt and HIF-1± Signaling Pathways. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10371.	4.1	11
165	Measurement of exhaled hydrogen peroxide from rabbit lungs. <i>Biological Chemistry</i> , 2004, 385, 259-264.	2.5	9
166	Prostanoids and Phosphodiesterase Inhibitors in Experimental Pulmonary Hypertension. <i>Current Topics in Developmental Biology</i> , 2005, 67, 251-284.	2.2	9
167	Effects of carbon monoxide-releasing molecules on pulmonary vasoreactivity in isolated perfused lungs. <i>Journal of Applied Physiology</i> , 2016, 120, 271-281.	2.5	9
168	Exercise Affects T-Cell Function by Modifying Intracellular Calcium Homeostasis. <i>Medicine and Science in Sports and Exercise</i> , 2017, 49, 29-39.	0.4	9
169	Circulating Apoptotic Signals During Acute and Chronic Exposure to High Altitude in Kyrgyz Population. <i>Frontiers in Physiology</i> , 2019, 10, 54.	2.8	9
170	Cytochrome P450 epoxygenase-derived 5,6-epoxyeicosatrienoic acid relaxes pulmonary arteries in normoxia but promotes sustained pulmonary vasoconstriction in hypoxia. <i>Acta Physiologica</i> , 2020, 230, e13521.	3.8	9
171	The effect of long-term doxycycline treatment in a mouse model of cigarette smoke-induced emphysema and pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L903-L915.	2.9	9
172	Epigenetic Regulation by <i>Suv4-20h1</i> in Cardiopulmonary Progenitor Cells Is Required to Prevent Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease. <i>Circulation</i> , 2021, 144, 1042-1058.	1.6	9
173	Reactive Oxygen Species Differentially Modulate the Metabolic and Transcriptomic Response of Endothelial Cells. <i>Antioxidants</i> , 2022, 11, 434.	5.1	9
174	Chronic Obstructive Pulmonary Disease and Pulmonary Vascular Disease. A Comorbidity?. <i>Annals of the American Thoracic Society</i> , 2018, 15, S278-S281.	3.2	8
175	Genetic deletion of p66shc and/or cyclophilin D results in decreased pulmonary vascular tone. <i>Cardiovascular Research</i> , 2022, 118, 305-315.	3.8	8
176	FGF10 Triggers <i>De Novo</i> Alveologenesi in a Bronchopulmonary Dysplasia Model: Impact on Resident Mesenchymal Niche Cells. <i>Stem Cells</i> , 2022, 40, 605-617.	3.2	8
177	Nitric Oxide-mediated Zinc Release. <i>Circulation Research</i> , 2008, 102, 1451-1454.	4.5	7
178	Mitochondrial complex II participates in normoxic and hypoxic regulation of ±-keto acids in the murine heart. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 49, 950-961.	1.9	7
179	IRAG1 Deficient Mice Develop PKG1±² Dependent Pulmonary Hypertension. <i>Cells</i> , 2020, 9, 2280.	4.1	7
180	Retinal tissue develops an inflammatory reaction to tobacco smoke and electronic cigarette vapor in mice. <i>Journal of Molecular Medicine</i> , 2021, 99, 1459-1469.	3.9	7

#	ARTICLE	IF	CITATIONS
181	Hypoxic pulmonary vasoconstriction–triggered by an increase in reactive oxygen species?. Novartis Foundation Symposium, 2006, 272, 196-208; discussion 208-17.	1.1	7
182	Mitochondrial Respiration in Peripheral Blood Mononuclear Cells Negatively Correlates with Disease Severity in Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2022, 11, 4132.	2.4	7
183	Novel Therapeutic Targets for the Treatment of Right Ventricular Remodeling: Insights from the Pulmonary Artery Banding Model. International Journal of Environmental Research and Public Health, 2021, 18, 8297.	2.6	6
184	Hypoxia in lung vascular biology and disease. Cardiovascular Research, 2006, 71, 618-619.	3.8	5
185	VEGF Receptor Inhibition As a Model of Pulmonary Hypertension in Mice. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1103-1105.	5.6	5
186	Genetic Deficiency and Pharmacological Stabilization of Mast Cells Ameliorate Pressure Overload-Induced Maladaptive Right Ventricular Remodeling in Mice. International Journal of Molecular Sciences, 2020, 21, 9099.	4.1	5
187	Update in Pulmonary Vascular Diseases and Right Ventricular Dysfunction 2019. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 22-28.	5.6	5
188	Alternative oxidase encoded by sequence-optimized and chemically-modified RNA transfected into mammalian cells is catalytically active. Gene Therapy, 2022, 29, 655-664.	4.5	5
189	Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD. Cells, 2022, 11, 2121.	4.1	5
190	Reply to Bogaard et al.: Emphysema Isâ€”at the Mostâ€”Only a Mild Phenotype in the Sugden/Hypoxia Rat Model of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1450-1452.	5.6	4
191	Lack of Contribution of p66shc to Pressure Overload-Induced Right Heart Hypertrophy. International Journal of Molecular Sciences, 2020, 21, 9339.	4.1	4
192	Therapeutic Potential of Regorafenibâ€”A Multikinase Inhibitor in Pulmonary Hypertension. International Journal of Molecular Sciences, 2021, 22, 1502.	4.1	4
193	Pulmonary Vascular Pressure Response to Acute Cold Exposure in Kyrgyz Highlanders. High Altitude Medicine and Biology, 2019, 20, 375-382.	0.9	3
194	A Microfluidic System for Simultaneous Raman Spectroscopy, Patchâ€”Clamp Electrophysiology, and Liveâ€”Cell Imaging to Study Key Cellular Events of Single Living Cells in Response to Acute Hypoxia. Small Methods, 2021, 5, e2100470.	8.6	3
195	Development of a Gas-Tight Microfluidic System for Raman Sensing of Single Pulmonary Arterial Smooth Muscle Cells Under Normoxic/Hypoxic Conditions. Sensors, 2018, 18, 3238.	3.8	2
196	Sex-specific differences in plasma levels of FXII, HK, and FXIIa-C1-esterase inhibitor complexes in community-acquired pneumonia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L764-L774.	2.9	2
197	Hypoxia-Dependent TRP Channel Function in Pulmonary Arterial Smooth Muscle Cells. Methods in Pharmacology and Toxicology, 2012, , 283-300.	0.2	0
198	Letter by HÃ¼ttemann et al Regarding Article, â€œNdufs2, a Core Subunit of Mitochondrial Complex I, Is Essential for Acute Oxygen-Sensing and Hypoxic Pulmonary Vasoconstrictionâ€• Circulation Research, 2019, 125, e33-e34.	4.5	0

#	ARTICLE	IF	CITATIONS
199	Classical transient receptor potential channel 6 (TRPC6) is essential for ischemiaâ€reperfusion injury of the lung. FASEB Journal, 2010, 24, 591.2.	0.5	0
200	Endoplasmic Reticulum-Mitochondrial Crosstalk in the Development of Idiopathic Pulmonary Fibrosis. , 2019, 73, .		0